Clinical Report: Effects of Tumor Immunotherapy on Renal Damage and Multi-Organ Outcomes
Background
Immune checkpoint inhibitors have significantly advanced cancer treatment, offering substantial survival benefits across various malignancies. However, they are associated with immune-related adverse events, particularly renal toxicities such as acute kidney injury.
Data Highlights
No numerical or trial data was provided in the source material.
Key Findings
ICIs are linked to acute kidney injury, particularly acute tubulointerstitial nephritis.
Multi-organ immune-related adverse events, including myocarditis, are common in patients receiving ICIs.
Approximately 2-5% of patients experience acute kidney injury with anti-PD-1/PD-L1 monotherapy.
Incidence of acute kidney injury increases to 4.9-29% with combination anti-PD-1/CTLA-4 therapies.
Mechanistic pathways include PD-1/PD-L1 signaling disruption and immune cell heterogeneity.
There is significant interstudy variability in quantitative effect estimates regarding nephrotoxicity.
Clinical Implications
Clinicians should be aware of the potential for renal and multi-organ adverse events when administering ICIs.
Conclusion
The impact of tumor immunotherapy on renal and multi-organ homeostasis is significant.
